US5135757A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compressible sustained release solid dosage forms
Assignee: Penwest Pharmaceuticals Co
•
Filing: 1991-01-16
•
Granted: 1992-08-04
•
Expires: 2011-01-16
Abstract
Abstract A free-flowing directly compressible granulation useful as a slow release pharmaceutical excipient is disclosed. The excipient includes a hydrodrophilic matrix which includes heteropolysaccharide and a polysaccharide material capable of cross-linking the heteropolysaccharide, and an inert diluent.
Inventors
- 👤 Anand R. Baichwal
- 👤 John N. Staniforth
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 18:10
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/2004; A61K9/2022; A61K9/205; A61K9/2013; A61K9/2018
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
210 words
A method for providing a univeral tableting granulated excipient which is free-flowing and directly compressible for a controlled release of a relatively soluble or insoluble therapeutically active medicament comprising determining the solubility of a therapeutically active medicament which is to be tableted; mixing an effective amount of said therapeutically active medicament to render a desired therapeutic effect with a premanufactured granulated slow release excipient comprising from about 30 to about 50 percent by weight of a hydrophilic material comprising from about 90 to about 10 percent by weight of a heteropolysaccharide and from about 10 to about 90 percent by weight of a cross-linking agent capable of cross-linking said heteropolysaccharide in the presence of gastric fluid and from about 50 to about 70 percent by weight of an inert pharmaceutical filler, providing a final mixed product having a ratio of said therapeutically active medicament to said hydrophilic material of about 1:3-7 and a sufficient amount of said hydrophilic material such that a gel matrix is created when said tablet is exposed to gastric fluid and such that at least 3.5 hours are required for 50 percent of said therapeutically active medicament to be released following exposure to gastric fluid, and thereafter directly compressing the resulting blend to form a tablet.
Claim 2
Independent Claim
210 words
A method for providing a univeral tableting granulated excipient which is free-flowing and directly compressible for a controlled release of a relatively soluble or insoluble therapeutically active medicament comprising determining the solubility of a therapeutically active medicament which is to be tableted; mixing an effective amount of said therapeutically active medicament to render a desired therapeutic effect with a premanufactured granulated slow release excipient comprising from about 30 to about 50 percent by weight of a hydrophilic material comprising from about 90 to about 10 percent by weight of a heteropolysaccharide and from about 10 to about 90 percent by weight of a cross-linking agent capable of cross-linking said heteropolysaccharide in the presence of gastric fluid and from about 50 to about 70 percent by weight of an inert pharmaceutical filler, providing a final mixed product having a ratio of said therapeutically active medicament to said hydrophilic material of about 1:3-7 and a sufficient amount of said hydrophilic material such that a gel matrix is created when said tablet is exposed to gastric fluid and such that at least 3.5 hours are required for 50 percent of said therapeutically active medicament to be released following exposure to gastric fluid, and thereafter directly compressing the resulting blend to form a tablet.
Claim 3
Dependent Claim
24 words
The method according to claim 1, wherein said heteropolysaccharide is xanthan gum and said cross-linking agent is locust bean gum in a 1:1 ratio.
Claim 4
Dependent Claim
25 words
The method according to claim 2, further comprising providing a tablet wherein said hydrophilic material constitutes at least 20 percent by weight of said tablet.
Claim 5
Independent Claim
165 words
A method of using a hydrophilic gum matrix to obtain a controlled-release oral solid dosage form comprising preparing a hydrophilic gum matrix comprising a xanthan gum and a galactomannan gum capable of cross-linking said xanthan gum when exposed to gastric fluid, the ratio of said xanthan gum to said galactomannan gum being from about 1:3 to about 3:1; mixing said hydrophilic gum matrix with an inert diluent selected from the group consisting of a monosaccharide, a disaccharide, a polyhydric alcohol, and mixtures thereof, in a ratio of said inert diluent to said hydrophilic gum matrix from about 4:1 to about 0.67:1; combining the mixture of hydrophilic gum matrix and inert diluent with an effective amount of a medicament to render a desired therapeutic effect via dry granulation, wet granulation or a combination of dry and wet granulation such that the ratio of said medicament to said hydrophilic gum matrix is from about 1:3 to about 1:7, and compressing the resultant mixture to form solid tablets.
Claim 6
Independent Claim
165 words
A method of using a hydrophilic gum matrix to obtain a controlled-release oral solid dosage form comprising preparing a hydrophilic gum matrix comprising a xanthan gum and a galactomannan gum capable of cross-linking said xanthan gum when exposed to gastric fluid, the ratio of said xanthan gum to said galactomannan gum being from about 1:3 to about 3:1; mixing said hydrophilic gum matrix with an inert diluent selected from the group consisting of a monosaccharide, a disaccharide, a polyhydric alcohol, and mixtures thereof, in a ratio of said inert diluent to said hydrophilic gum matrix from about 4:1 to about 0.67:1; combining the mixture of hydrophilic gum matrix and inert diluent with an effective amount of a medicament to render a desired therapeutic effect via dry granulation, wet granulation or a combination of dry and wet granulation such that the ratio of said medicament to said hydrophilic gum matrix is from about 1:3 to about 1:7, and compressing the resultant mixture to form solid tablets.
Claim 7
Independent Claim
112 words
A method for preparing a controlled release solid dosage form, comprising mixing a sufficient amount of a therapeutically active medicament to render a desired therapeutic effect with a granulated slow release excipient comprising from about 30 to about 50 percent by weight a heteropolysaccharide comprising from about 90 to about 10 percent by weight xanthan gum and from about 10 to about 90 percent by weight locust bean gum, with from about 50 to about 70 percent by weight of an inert pharmaceutical filler, and preparing a final mixed solid product which, when exposed to gastric fluid, requires at least 3.5 hours to release about 50 percent of said therapeutically active medicament.
Claim 8
Independent Claim
112 words
A method for preparing a controlled release solid dosage form, comprising mixing a sufficient amount of a therapeutically active medicament to render a desired therapeutic effect with a granulated slow release excipient comprising from about 30 to about 50 percent by weight a heteropolysaccharide comprising from about 90 to about 10 percent by weight xanthan gum and from about 10 to about 90 percent by weight locust bean gum, with from about 50 to about 70 percent by weight of an inert pharmaceutical filler, and preparing a final mixed solid product which, when exposed to gastric fluid, requires at least 3.5 hours to release about 50 percent of said therapeutically active medicament.
Claim 9
Dependent Claim
22 words
The method of claim 5, wherein the ratio of xanthan gum to locust bean gum in from about 1:3 to about 3:1.
Claim 10
Dependent Claim
17 words
The method of claim 5, further comprising compressing the final mixed solid product to form solid tablets.
References Cited (Backward Citations)
US2993836A
Cited
US3079303A
Cited
US3074852A
Cited
US3133863A
Cited
US3147187A
Cited
US3388041A
Cited
GB1097207A
Cited
US3456049A
Cited
US3726690A
Cited
US3864469A
Cited
US3627583A
Cited
US3639169A
Cited
US3629393A
Cited
US3728445A
Cited
US4072535A
Cited
US3773920A
Cited
US3836618A
Cited
US3950508A
Cited
US3963832A
Cited
US4013820A
Cited
US4167558A
Cited
US4199560A
Cited
US4361545A
Cited
US4259314A
Cited
US4308251A
Cited
US4439453A
Cited
US4542011A
Cited
US4424235A
Cited
US4525345A
Cited
US4389393A
Cited
US4389393B1
Cited
WO1984000104A1
Cited
US4556678A
Cited
US4698264A
Cited
US4698101A
Cited
US4692337A
Cited
US4717713A
Cited
US4623394A
Cited
US4590062A
Cited
US4695467A
Cited
US4762702A
Cited
US4695463A
Cited
WO1987000044A1
Cited
GB2178658A
Cited
US4755389A
Cited
US4704285A
Cited
US4855143A
Cited
US4829056A
Cited
US4828836A
Cited
US4803077A
Cited
US4792452A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-08-04 | 1996-02-03 | 1996-08-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-08-04 | 2000-02-03 | 2000-08-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-08-04 | 2004-02-03 | 2004-08-04 | $7700.00 | Window Closed / Lapsed |